Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244516 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL21458805 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL5250584 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL8403603 | 0.91 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL10815020 | 0.91 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL22631510 | 0.88 | EPHX1 (0.55) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL852267 | 0.86 | — | — | |
| SCHEMBL21001065 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL27700989 | 0.84 | — | — | |
| SCHEMBL16541245 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148733-A1 | COMBINATION THERAPY | GENENTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4340883-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4114830-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Genentech, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022246459-A9 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022246459-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
| US-20240148733-A1 | COMBINATION THERAPY | KRAS, YAP1, HRAS | CHRNB2 4554/4885CHRNA4 4738/4885MAPK1 1138/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | CHRNB2 4688/4885CHRNA4 4837/4885MAPK1 2821/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885MAPK1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.